Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg.

What is bexobrutideg?

Bexobrutideg is an orally bioavailable, brain-penetrant BTK degrader that works differently from conventional BTK inhibitors currently on the market. Rather than simply blocking BTK's kinase activity, bexobrutideg harnesses the body's natural protein disposal system to eliminate the BTK protein from cells entirely, removing both its kinase and scaffolding functions.² That distinction is clinically meaningful because many patients on existing BTK inhibitors eventually develop resistance mutations that render those drugs less effectively, and by degrading the protein rather than just inhibiting it, bexobrutideg has the potential to overcome those resistance mechanisms.²

Phase III clinical trial initiation in second-line CLL is planned for summer 2026, with available clinical data suggesting the drug could offer higher efficacy and more favorable tolerability than current standard-of-care BTK inhibitors, according to Roche.¹

"We believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases," said Levi Garraway, Roche's chief medical officer and head of global product development.

What are the details of the deal?

Under the terms of the agreement, Nurix is set to receive an upfront cash payment upwards of $700 million, with the remainder tied to development, regulatory, and sales milestones.¹ Development costs will be shared 60% by Roche and 40% by Nurix, with U.S. commercialization profits and losses split equally between the two companies. Outside the U.S., Roche will handle commercialization while Nurix receives royalties ranging from the low- to high-teens.¹

The transaction is expected to close in the third quarter of 2026, pending antitrust clearance.

Why is this deal strategically significant?

The collaboration adds a potentially best-in-class asset to Roche's already established hematology portfolio and also opens two additional therapeutic avenues in immunology and neurology where BTK has emerged as a relevant target.¹ BTK functions as a central signaling node not only in B-cell cancers but also in immune-mediated conditions such as chronic spontaneous urticaria and neurological diseases such as multiple sclerosis, which affects nearly 3 million people worldwide, and Bexobrutideg's brain-penetrant properties and ability to degrade BTK across immune cell types give it potential reach in those indications that conventional inhibitors have not demonstrated.¹

For Nurix, the partnership provides the global development infrastructure and commercial reach needed to advance bexobrutideg at scale. "Roche is the ideal partner to help translate the promise of targeted protein degradation into meaningful impact for patients worldwide," said Arthur T. Sands, MD, PhD, president and CEO of Nurix. "Collaborating with Roche uniquely enables our ability to extend the cross-therapeutic opportunity of bexobrutideg in immunology and neurology."

The timing of the deal also reflects the growing commercial stakes in the BTK space. The combined NHL and CLL market is projected to reach $41 billion by 2031, with BTK inhibitors expected to remain the sales-leading drug class at approximately $19 billion.¹

The CLL segment alone is forecast to grow from $12 billion in 2024 to $16 billion by 2035, and despite those advances, significant unmet need persists, such as CLL patients ultimately experiencing disease progression due to acquired resistance mutations, incomplete pathway suppression, or tolerability issues that limit long-term use, leaving few options once relapse occurs.

Sources

1. Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology Roche June 8, 2026 https://www.globenewswire.com/news-release/2026/06/08/3307778/0/en/roche-announces-global-collaboration-with-nurix-therapeutics-to-co-develop-and-co-commercialise-potential-best-in-class-btk-degrader-bexobrutideg-across-malignant-haematology-immun.html
2. Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial ASH Publications November 3, 2025 https://ashpublications.org/blood/article/146/Supplement%201/86/549702/Bexobrutideg-NX-5948-a-novel-Bruton-s-tyrosine